Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Burkitt Lymphoma 7Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Blast Crisis 6Sezary Syndrome 5Prostatic Neoplasms 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, B-Cell, Marginal Zone 5Brain Neoplasms 5

Interventions

Granulocyte Colony-Stimulating Factor 5Filgrastim 5Cyclophosphamide 5Melphalan 4Busulfan 4Mesna 3Ifosfamide 3Etoposide 3Carboplatin 3sargramostim 2fludarabine 2Vorinostat 2Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Sirolimus 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2Flow Cytometry 2Cisplatin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1tariquidar 1regorafenib 1racotumomab 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Wilms Tumor × Vorinostat × Clear all
NCT04308330 2026-04-15

NYMC195

New York Medical College

Phase 1 Recruiting
30 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT01132911 2017-07-02

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡